We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.05 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
From Apr 2019 to Apr 2024
TIDMRENE
RNS Number : 5752Y
ReNeuron Group plc
09 May 2019
9 May 2019 AIM: RENE
ReNeuron Group plc
Exercise of options, PDMR dealing and
total voting rights
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has received notices to exercise options from certain PDMRs of the Company to subscribe for a total of 65,792 new ordinary shares of 1 pence each in the Company ("Ordinary Shares").
On 9 May 2019, Sharon Grimster, VP Development and General Manager Wales, exercised options over 39,960 Ordinary Shares at an exercise price of 100 pence per share. Subsequently, on 9 May 2019, Mrs Grimster sold 39,960 Ordinary Shares at a share price of 267 pence.
On 9 May 2019, Dr Randolph Corteling, Head of Research, exercised options over 25,832 Ordinary Shares at an exercise price of 100 pence per share. Subsequently, on 9 May 2019, Dr Corteling sold 25,832 Ordinary Shares at a share price of 267 pence.
Total voting rights
Following the issue of 65,792 Ordinary Shares pursuant to the exercise of options described above, together with exercise of options by other staff under its existing blocklisting arrangements, the Company has 31,799,617 ordinary shares of 1 pence each in issue, all with voting rights. The Company holds no ordinary shares in treasury. The above figure of 31,799,617 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
SENQUIRIES:
ReNeuron +44 (0)20 3819 8400 Olav Hellebø, Chief Executive Officer Michael Hunt, Chief Financial Officer Buchanan +44 (0) 20 7466 5000 Mark Court, Sophie Wills, Tilly Abraham Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600 Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) N+1 Singer +44 (0) 20 7496 3000 Aubrey Powell, Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.
Hot Features
Premium
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sharon Grimster
--------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status VP Development and General Manager
Wales
--------------------------- -----------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- -----------------------------------
b) LEI 2138003TU12CQ5TZO137
--------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial instrument,
type of instrument RENE - GB00BF5G6K95
Identification
code
--------------------------- -----------------------------------
b) Nature of the transaction Exercise of options over ordinary
shares
--------------------------- -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
100 pence 39,960
----------
--------------------------- -----------------------------------
d) Aggregated information N/A
--------------------------- -----------------------------------
e) Date of the transaction 09 May 2019
--------------------------- -----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------- -----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sharon Grimster
--------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status VP Development and General Manager
Wales
--------------------------- -----------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- -----------------------------------
b) LEI 2138003TU12CQ5TZO137
--------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial instrument,
type of instrument RENE - GB00BF5G6K95
Identification
code
--------------------------- -----------------------------------
b) Nature of the transaction Sale of ordinary shares
--------------------------- -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
267 pence 39,960
----------
--------------------------- -----------------------------------
d) Aggregated information N/A
--------------------------- -----------------------------------
e) Date of the transaction 09 May 2019
--------------------------- -----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------- -----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Randolph Corteling
---------------------------- ----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Head of Research
---------------------------- ----------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
---------------------------- ----------------------------------
b) LEI 2138003TU12CQ5TZO137
---------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial instrument,
type of instrument RENE - GB00BF5G6K95
Identification
code
---------------------------- ----------------------------------
b) Nature of the transaction Exercise of options over ordinary
shares
---------------------------- ----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
100 pence 25,832
----------
---------------------------- ----------------------------------
d) Aggregated information N/A
---------------------------- ----------------------------------
e) Date of the transaction 09 May 2019
---------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
---------------------------- ----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Randolph Corteling
---------------------------- ----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Head of Research
---------------------------- ----------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
---------------------------- ----------------------------------
b) LEI 2138003TU12CQ5TZO137
---------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial instrument,
type of instrument RENE - GB00BF5G6K95
Identification
code
---------------------------- ----------------------------------
b) Nature of the transaction Sale of ordinary shares
---------------------------- ----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
267 pence 25,832
----------
---------------------------- ----------------------------------
d) Aggregated information N/A
---------------------------- ----------------------------------
e) Date of the transaction 09 May 2019
---------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
---------------------------- ----------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCEAKSNEEANEFF
(END) Dow Jones Newswires
May 09, 2019 12:05 ET (16:05 GMT)
1 Year Reneuron Chart |
1 Month Reneuron Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
